Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthracycline cardiomyopathy

N L Kobrinsky, N K Ramsay, W Krivit

    Pediatric Cardiology
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Anthracycline chemotherapy can cause irreversible heart damage in children. Identifying risk factors and exploring protective agents like free radical scavengers are crucial for improving treatment safety.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.

    Cancer biotherapy & radiopharmaceuticals·2003
    Same author

    Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.

    Transplant infectious disease : an official journal of the Transplantation Society·2003
    Same author

    Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

    Bone marrow transplantation·2002
    Same author

    Outcome of second hematopoietic cell transplantation in Hurler syndrome.

    Bone marrow transplantation·2002
    Same author

    Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation.

    Bone marrow transplantation·2002
    Same author

    Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome.

    The American journal of cardiology·2001
    Same journal

    Association of Race and Ethnicity with the Diagnosis and Management of Wolff-Parkinson-White Pattern in Children.

    Pediatric cardiology·2026
    Same journal

    Fenestrated PECA exGraft Patch as a Novel Modifiable Internal Pulmonary Artery Band: A Case Report.

    Pediatric cardiology·2026
    Same journal

    Selective Activation of the Tryptophan-Kynurenine Pathway in Fontan Circulation.

    Pediatric cardiology·2026
    Same journal

    Intubation Prior to Tetralogy of Fallot with Absent Pulmonary Valve Surgery: A Tale of Two Ventilation Pathways.

    Pediatric cardiology·2026
    Same journal

    Bile Acid Pool Expansion and Hemodynamic Associations of the Secondary-to-Primary Bile Acid Ratio in Adult Fontan Circulation.

    Pediatric cardiology·2026
    Same journal

    Correction: Adenosine Dose and Cardioversion in Pediatric Supraventricular Tachycardia: A Systematic Review and Meta-Analysis.

    Pediatric cardiology·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Background:

    • Anthracycline chemotherapy is associated with life-threatening cardiomyopathy, especially in pediatric patients.
    • Understanding risk factors, pharmacokinetics, and toxicity mechanisms is key to managing anthracycline-induced cardiotoxicity.
    • Current management strategies and clinical trial designs need refinement to address this complication.

    Purpose of the Study:

    • To review risk factors and management strategies for anthracycline-induced cardiomyopathy in pediatric patients.
    • To explore potential cardioprotective agents and novel anthracycline analogs.
    • To highlight the need for improved clinical trial designs and pediatric protocols.

    Main Methods:

    • Review of identified risk factors, drug pharmacokinetics, and mechanisms of action.

    Related Experiment Videos

  • Discussion of potential cardioprotective strategies, including free radical scavengers and cardiac glycosides.
  • Analysis of challenges in interpreting clinical trials and the need for large-scale pediatric studies.

    • Main Results:

    • Numerous risk factors for anthracycline cardiotoxicity have been identified.
    • Potential cardioprotective agents like alpha-tocopherol and coenzyme Q10 may mitigate myocardial damage.
    • Anthracycline analogs are being developed to reduce cardiotoxicity while maintaining efficacy.

    Conclusions:

    • Pediatric cardiologists and oncologists must collaborate to manage patients receiving anthracyclines.
    • Further clinical investigation into cardioprotective agents and optimized dosing is essential.
    • Well-designed pediatric clinical trials are urgently needed to improve the therapeutic index of anthracyclines.